- Main
A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance
- Warshauer, Jeremy T;
- Belk, Julia A;
- Chan, Alice Y;
- Wang, Jiaxi;
- Gupta, Alexander R;
- Shi, Quanming;
- Skartsis, Nikolaos;
- Peng, Yani;
- Phipps, Jonah D;
- Acenas, Dante;
- Smith, Jennifer A;
- Tamaki, Stanley J;
- Tang, Qizhi;
- Gardner, James M;
- Satpathy, Ansuman T;
- Anderson, Mark S
Published Web Location
https://doi.org/10.1084/jem.20210759Abstract
Naturally occurring cases of monogenic type 1 diabetes (T1D) help establish direct mechanisms driving this complex autoimmune disease. A recently identified de novo germline gain-of-function (GOF) mutation in the transcriptional regulator STAT3 was found to cause neonatal T1D. We engineered a novel knock-in mouse incorporating this highly diabetogenic human STAT3 mutation (K392R) and found that these mice recapitulated the human autoimmune diabetes phenotype. Paired single-cell TCR and RNA sequencing revealed that STAT3-GOF drives proliferation and clonal expansion of effector CD8+ cells that resist terminal exhaustion. Single-cell ATAC-seq showed that these effector T cells are epigenetically distinct and have differential chromatin architecture induced by STAT3-GOF. Analysis of islet TCR clonotypes revealed a CD8+ cell reacting against known antigen IGRP, and STAT3-GOF in an IGRP-reactive TCR transgenic model demonstrated that STAT3-GOF intrinsic to CD8+ cells is sufficient to accelerate diabetes onset. Altogether, these findings reveal a diabetogenic CD8+ T cell response that is restrained in the presence of normal STAT3 activity and drives diabetes pathogenesis.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.